PDF(Pubmed)
Abstract：
UNASSIGNED: The objective of this case series is to investigate the efficacy and safety of intravenous infusion of Pamidronate, a second generation bisphosphonate, in the treatment of active Charcot arthropathy.
UNASSIGNED: All patients with active Charcot arthropathy treated at the medical centre from 1 January 2013 to 30 June 2020 were included in the study. Efficacy outcome was evaluated based on time to consolidate findings observed through radiographic examination, while safety outcome was evaluated based on the incidence of adverse event (AE) occurrence.
UNASSIGNED: A total of 81 patients (37 male, 44 female) diagnosed with active Charcot arthropathy were included. 64.2% of patients were at stage 1 of Charcot arthropathy whereas 35.8% were at stage 2. The mean time to consolidate for stage 1 and stage 2 was 6.50 ± 4.21 months and 3.63 ± 2.92 months respectively (p-value = 0.139). No significant association was observed between gender, ethnicity and disease stage with the consolidation time (p-value >0.05). The rate of AE incidence was 2.5%, observed in 2 patients who developed a fever during the treatment. No other serious AE was observed in the study.
UNASSIGNED: Intravenous Pamidronate infusion is a safe and effective treatment option for Charcot arthropathy.
UNASSIGNED: All patients with active Charcot arthropathy treated at the medical centre from 1 January 2013 to 30 June 2020 were included in the study. Efficacy outcome was evaluated based on time to consolidate findings observed through radiographic examination, while safety outcome was evaluated based on the incidence of adverse event (AE) occurrence.
UNASSIGNED: A total of 81 patients (37 male, 44 female) diagnosed with active Charcot arthropathy were included. 64.2% of patients were at stage 1 of Charcot arthropathy whereas 35.8% were at stage 2. The mean time to consolidate for stage 1 and stage 2 was 6.50 ± 4.21 months and 3.63 ± 2.92 months respectively (p-value = 0.139). No significant association was observed between gender, ethnicity and disease stage with the consolidation time (p-value >0.05). The rate of AE incidence was 2.5%, observed in 2 patients who developed a fever during the treatment. No other serious AE was observed in the study.
UNASSIGNED: Intravenous Pamidronate infusion is a safe and effective treatment option for Charcot arthropathy.
摘要：
■本病例系列的目的是研究静脉输注帕米膦酸盐的疗效和安全性，第二代双膦酸盐，用于治疗活动性Charcot关节病。
2013年1月1日至2020年6月30日在医疗中心治疗的所有活动性Charcot关节病患者均纳入研究。根据通过影像学检查观察到的巩固结果的时间来评估疗效结果。而安全性结局是根据不良事件（AE）的发生率进行评估的。
■共有81名患者（37名男性，包括44名女性）诊断为活动性Charcot关节病。64.2％的患者处于Charcot关节病的1期，而35.8％的患者处于2期。第1阶段和第2阶段的平均巩固时间分别为6.50±4.21个月和3.63±2.92个月（p值=0.139）。没有观察到性别之间的显著关联，种族和疾病分期与巩固时间（p值>0.05）。AE发生率为2.5%,在治疗期间出现发烧的2例患者中观察到。在研究中没有观察到其他严重的AE。
■静脉输注帕米膦酸钠是治疗Charcot关节病的一种安全有效的选择。
2013年1月1日至2020年6月30日在医疗中心治疗的所有活动性Charcot关节病患者均纳入研究。根据通过影像学检查观察到的巩固结果的时间来评估疗效结果。而安全性结局是根据不良事件（AE）的发生率进行评估的。
■共有81名患者（37名男性，包括44名女性）诊断为活动性Charcot关节病。64.2％的患者处于Charcot关节病的1期，而35.8％的患者处于2期。第1阶段和第2阶段的平均巩固时间分别为6.50±4.21个月和3.63±2.92个月（p值=0.139）。没有观察到性别之间的显著关联，种族和疾病分期与巩固时间（p值>0.05）。AE发生率为2.5%,在治疗期间出现发烧的2例患者中观察到。在研究中没有观察到其他严重的AE。
■静脉输注帕米膦酸钠是治疗Charcot关节病的一种安全有效的选择。
